Inflammatory myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome

Objectives. Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue diseases or neoplasia. A large variety of autoantibodies can be detected in patients with myositis, some of which have a diagnostic and/or a progn...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 41; no. 9; pp. 1040 - 1046
Main Authors Coppo, P., Clauvel, J. P., Bengoufa, D., Oksenhendler, E., Lacroix, C., Lassoued, K.
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.09.2002
Oxford Publishing Limited (England)
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objectives. Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue diseases or neoplasia. A large variety of autoantibodies can be detected in patients with myositis, some of which have a diagnostic and/or a prognostic value. Myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies (anti‐U1‐snRNP Abs) are usually considered as overlapping syndromes, mainly mixed connective tissue diseases (MCTD) in which muscle symptoms occur insidiously during the disease course and are characterized by a favourable outcome. Methods. The clinical, biological, immunological and pathological findings as well as the outcome of five patients with anti‐U1‐snRNP‐associated myositis were retrospectively analysed. Results. Patients were mainly black females. In all five patients, myositis was the predominant manifestation at presentation. Associated conditions consisted of interstitial lung disease (ILD) (three), arthritis (three) and neurological symptoms (two). No patient presented Raynaud's phenomenon nor met criteria for MCTD. Biological inflammatory features, rheumatoid factor and polyclonal hypergammaglobulinaemia were present in all cases. Besides anti‐U1‐snRNP Abs, one patient had anti‐Ro/SSA and anti‐La/SSB Abs at presentation and one additional patient developed anti‐double‐stranded‐DNA and anti‐Sm Abs after a follow‐up of more than 4 yr. No patient had anti‐PM/sclerosis (Scl) nor anti‐aminoacyl‐tRNA synthetase Abs. All patients dramatically improved with steroids, and reached complete remission (CR) within 3 weeks. Two patients relapsed 18 months after CR. They both reached rapidly second CR using steroids associated or not with oral methotrexate. Conclusion. Our data suggest that anti‐U1‐snRNP Abs may define a subset of myositis characterized by a favourable outcome, though often associated with ILD and/or neurological manifestations.
AbstractList Objectives. Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue diseases or neoplasia. A large variety of autoantibodies can be detected in patients with myositis, some of which have a diagnostic and/or a prognostic value. Myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies (anti-U1-snRNP Abs) are usually considered as overlapping syndromes, mainly mixed connective tissue diseases (MCTD) in which muscle symptoms occur insidiously during the disease course and are characterized by a favourable outcome. Methods. The clinical, biological, immunological and pathological findings as well as the outcome of five patients with anti-U1-snRNP-associated myositis were retrospectively analysed. Results. Patients were mainly black females. In all five patients, myositis was the predominant manifestation at presentation. Associated conditions consisted of interstitial lung disease (ILD) (three), arthritis (three) and neurological symptoms (two). No patient presented Raynaud's phenomenon nor met criteria for MCTD. Biological inflammatory features, rheumatoid factor and polyclonal hypergammaglobulinaemia were present in all cases. Besides anti-U1-snRNP Abs, one patient had anti-Ro/SSA and anti-La/SSB Abs at presentation and one additional patient developed anti-double-stranded-DNA and anti-Sm Abs after a follow-up of more than 4 yr. No patient had anti-PM/sclerosis (Scl) nor anti-aminoacyl-tRNA synthetase Abs. All patients dramatically improved with steroids, and reached complete remission (CR) within 3 weeks. Two patients relapsed 18 months after CR. They both reached rapidly second CR using steroids associated or not with oral methotrexate. Conclusion. Our data suggest that anti-U1-snRNP Abs may define a subset of myositis characterized by a favourable outcome, though often associated with ILD and/or neurological manifestations.
Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue diseases or neoplasia. A large variety of autoantibodies can be detected in patients with myositis, some of which have a diagnostic and/or a prognostic value. Myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies (anti-U1-snRNP Abs) are usually considered as overlapping syndromes, mainly mixed connective tissue diseases (MCTD) in which muscle symptoms occur insidiously during the disease course and are characterized by a favourable outcome. The clinical, biological, immunological and pathological findings as well as the outcome of five patients with anti-U1-snRNP-associated myositis were retrospectively analysed. Patients were mainly black females. In all five patients, myositis was the predominant manifestation at presentation. Associated conditions consisted of interstitial lung disease (ILD) (three), arthritis (three) and neurological symptoms (two). No patient presented Raynaud's phenomenon nor met criteria for MCTD. Biological inflammatory features, rheumatoid factor and polyclonal hypergammaglobulinaemia were present in all cases. Besides anti-U1-snRNP Abs, one patient had anti-Ro/SSA and anti-La/SSB Abs at presentation and one additional patient developed anti-double-stranded-DNA and anti-Sm Abs after a follow-up of more than 4 yr. No patient had anti-PM/sclerosis (Scl) nor anti-aminoacyl-tRNA synthetase Abs. All patients dramatically improved with steroids, and reached complete remission (CR) within 3 weeks. Two patients relapsed 18 months after CR. They both reached rapidly second CR using steroids associated or not with oral methotrexate. Our data suggest that anti-U1-snRNP Abs may define a subset of myositis characterized by a favourable outcome, though often associated with ILD and/or neurological manifestations.
OBJECTIVESInflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue diseases or neoplasia. A large variety of autoantibodies can be detected in patients with myositis, some of which have a diagnostic and/or a prognostic value. Myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies (anti-U1-snRNP Abs) are usually considered as overlapping syndromes, mainly mixed connective tissue diseases (MCTD) in which muscle symptoms occur insidiously during the disease course and are characterized by a favourable outcome.METHODSThe clinical, biological, immunological and pathological findings as well as the outcome of five patients with anti-U1-snRNP-associated myositis were retrospectively analysed.RESULTSPatients were mainly black females. In all five patients, myositis was the predominant manifestation at presentation. Associated conditions consisted of interstitial lung disease (ILD) (three), arthritis (three) and neurological symptoms (two). No patient presented Raynaud's phenomenon nor met criteria for MCTD. Biological inflammatory features, rheumatoid factor and polyclonal hypergammaglobulinaemia were present in all cases. Besides anti-U1-snRNP Abs, one patient had anti-Ro/SSA and anti-La/SSB Abs at presentation and one additional patient developed anti-double-stranded-DNA and anti-Sm Abs after a follow-up of more than 4 yr. No patient had anti-PM/sclerosis (Scl) nor anti-aminoacyl-tRNA synthetase Abs. All patients dramatically improved with steroids, and reached complete remission (CR) within 3 weeks. Two patients relapsed 18 months after CR. They both reached rapidly second CR using steroids associated or not with oral methotrexate.CONCLUSIONOur data suggest that anti-U1-snRNP Abs may define a subset of myositis characterized by a favourable outcome, though often associated with ILD and/or neurological manifestations.
Objectives. Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue diseases or neoplasia. A large variety of autoantibodies can be detected in patients with myositis, some of which have a diagnostic and/or a prognostic value. Myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies (anti‐U1‐snRNP Abs) are usually considered as overlapping syndromes, mainly mixed connective tissue diseases (MCTD) in which muscle symptoms occur insidiously during the disease course and are characterized by a favourable outcome. Methods. The clinical, biological, immunological and pathological findings as well as the outcome of five patients with anti‐U1‐snRNP‐associated myositis were retrospectively analysed. Results. Patients were mainly black females. In all five patients, myositis was the predominant manifestation at presentation. Associated conditions consisted of interstitial lung disease (ILD) (three), arthritis (three) and neurological symptoms (two). No patient presented Raynaud's phenomenon nor met criteria for MCTD. Biological inflammatory features, rheumatoid factor and polyclonal hypergammaglobulinaemia were present in all cases. Besides anti‐U1‐snRNP Abs, one patient had anti‐Ro/SSA and anti‐La/SSB Abs at presentation and one additional patient developed anti‐double‐stranded‐DNA and anti‐Sm Abs after a follow‐up of more than 4 yr. No patient had anti‐PM/sclerosis (Scl) nor anti‐aminoacyl‐tRNA synthetase Abs. All patients dramatically improved with steroids, and reached complete remission (CR) within 3 weeks. Two patients relapsed 18 months after CR. They both reached rapidly second CR using steroids associated or not with oral methotrexate. Conclusion. Our data suggest that anti‐U1‐snRNP Abs may define a subset of myositis characterized by a favourable outcome, though often associated with ILD and/or neurological manifestations.
Author Clauvel, J. P.
Bengoufa, D.
Coppo, P.
Lassoued, K.
Lacroix, C.
Oksenhendler, E.
Author_xml – sequence: 1
  givenname: P.
  surname: Coppo
  fullname: Coppo, P.
– sequence: 2
  givenname: J. P.
  surname: Clauvel
  fullname: Clauvel, J. P.
– sequence: 3
  givenname: D.
  surname: Bengoufa
  fullname: Bengoufa, D.
  organization: Service d'Immuno‐Hématologie, Laboratoire d'Immunologie, Hôpital Saint‐Louis, Paris and
– sequence: 4
  givenname: E.
  surname: Oksenhendler
  fullname: Oksenhendler, E.
– sequence: 5
  givenname: C.
  surname: Lacroix
  fullname: Lacroix, C.
  organization: Laboratoire d'Anatomo‐Pathologie, Hôpital de Bicêtre, le Kremlin Bicêtre, France
– sequence: 6
  givenname: K.
  surname: Lassoued
  fullname: Lassoued, K.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13912541$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/12209039$$D View this record in MEDLINE/PubMed
BookMark eNqF0ctqFjEUB_AgFXvRVyhB0N20uc-MOym94QduLIqb4UwuNjUzqUlG_XY-gjvfzycxbT8ruNBNckh-_Dkn2UVbc5wtQvuUHFDS88N0aZcJSgzxw_pQ0IO-HgvyAO1QoVhDOGdb9zUT22g35ytCiKS8e4S2KWOkJ7zfQT_OZxdguolKazytY_bFZww5R-2hWIO_-HKJYS7-57fvF7QueYIQ8LzoYCHh5Md4W8frFIv1860do_E2v8CA8zJmW3B0_wjHDj7HJcEYLI5L0XGyj9FDByHbJ5t9D12cHL85OmtWr0_Pj16uGi06WhqpBdMMrJDEttx1hjFnekpZZ6zsjBgdAa2g7UbiRH0IZYxWVinnWmGMYXwPPb_Lrd1_Wmwuw-SztiHAbOOSh5YR2UrZ_xcySgVr6Q18-he8qrPNdYiB9lIpphipaH-DlnGyZrhOfoK0Hn5_TAXPNgCyhuASzNrnP473lElBq2vunM_Ffr2_h_RxUC1v5XD27v2gxOmrt93JaljxXwX6tuw
CitedBy_id crossref_primary_10_1016_j_jbspin_2006_04_005
crossref_primary_10_1177_0961203319883936
crossref_primary_10_2169_internalmedicine_3626_19
crossref_primary_10_1038_s41380_019_0516_z
crossref_primary_10_1016_j_ejim_2004_08_009
crossref_primary_10_4078_jrd_2019_26_3_165
crossref_primary_10_1016_j_jaut_2019_04_001
crossref_primary_10_1016_j_jbspin_2019_01_013
crossref_primary_10_1016_j_jtauto_2022_100143
crossref_primary_10_1016_j_jbspin_2017_03_005
crossref_primary_10_1111_joim_12451
crossref_primary_10_1177_1759720X231181336
crossref_primary_10_4137_CCRPM_S36748
crossref_primary_10_1016_j_rhum_2017_01_013
crossref_primary_10_1186_s12948_018_0084_9
crossref_primary_10_1093_mrcr_rxad068
crossref_primary_10_1111_j_0105_2896_2009_00863_x
crossref_primary_10_1007_s12519_019_00313_8
crossref_primary_10_1016_j_autrev_2021_102851
crossref_primary_10_7861_clinmedicine_17_4_322
crossref_primary_10_2478_rir_2022_0001
crossref_primary_10_1212_WNL_0000000000007188
crossref_primary_10_1016_j_semarthrit_2023_152227
crossref_primary_10_1016_j_rhum_2006_04_009
crossref_primary_10_1002_art_22237
crossref_primary_10_1155_2021_5513544
crossref_primary_10_1016_j_jtauto_2019_100018
crossref_primary_10_1016_j_rcreu_2023_08_003
crossref_primary_10_1016_j_autrev_2017_07_013
crossref_primary_10_1080_14737175_2019_1572507
crossref_primary_10_1016_S0755_4982_06_74663_2
crossref_primary_10_1016_j_autrev_2020_102465
crossref_primary_10_1016_j_revmed_2013_12_006
crossref_primary_10_1016_j_rdc_2005_04_005
crossref_primary_10_1177_0961203310376637
crossref_primary_10_1016_j_lpm_2010_06_008
crossref_primary_10_1016_j_rdc_2005_04_003
ContentType Journal Article
Copyright 2002 INIST-CNRS
Copyright Oxford University Press(England) Sep 2002
Copyright_xml – notice: 2002 INIST-CNRS
– notice: Copyright Oxford University Press(England) Sep 2002
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QP
K9.
NAPCQ
7TM
7X8
DOI 10.1093/rheumatology/41.9.1040
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Calcium & Calcified Tissue Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList Nucleic Acids Abstracts
MEDLINE
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1462-0332
EndPage 1046
ExternalDocumentID 332920231
12209039
13912541
ark_67375_HXZ_64GKW8FL_L
Genre Journal Article
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
08P
0R~
18M
1TH
29P
2WC
354
3O-
4.4
48X
53G
5RE
5VS
5WA
5WD
70D
AABJS
AABMN
AABZA
AACZT
AAESY
AAGKA
AAIYJ
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUQX
AAVAP
AAWDT
AAWTL
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQTQ
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACIMA
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEIU
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADORX
ADQLU
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFXAL
AFXEN
AGINJ
AGKEF
AGSYK
AGUTN
AHMBA
AHXPO
AIAGR
AIJHB
AIKOY
AIMBJ
AJEEA
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APWMN
AQDSO
ASMCH
ATTQO
AWCFO
AXUDD
AZFZN
AZQFJ
BAWUL
BAYMD
BCRHZ
BEYMZ
BGYMP
BHONS
BSCLL
BTRTY
BVRKM
BYORX
C45
CAG
CASEJ
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DPORF
DPPUQ
DU5
D~K
E3Z
EBD
EBS
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
KAQDR
KBUDW
KC5
KOP
KQ8
KSI
KSN
L7B
M-Z
MHKGH
N9A
NGC
NOMLY
NOYVH
NTWIH
NVLIB
O0~
O9-
OAUYM
OAWHX
OBH
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RHF
RIG
RNI
ROL
ROX
RUSNO
RW1
RXO
RZF
RZO
SV3
TCURE
TEORI
TJX
TMA
TR2
VVN
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZY1
~91
AANRK
AAPBV
ABPTK
ALXQX
H13
IQODW
OBFPC
AAUAY
ABQNK
ADQBN
AEHUL
ATGXG
CGR
CUY
CVF
ECM
EIF
M49
NPM
NU-
7QP
K9.
NAPCQ
7TM
7X8
ID FETCH-LOGICAL-c481t-5c42c2ae450e73f8d22fd91128de58d4bf0ac6a78b0f43246ddc6e66ff74ddd23
ISSN 1462-0324
IngestDate Sat Aug 17 00:40:58 EDT 2024
Thu Jul 25 11:59:51 EDT 2024
Thu Oct 10 16:33:34 EDT 2024
Wed Oct 16 00:50:54 EDT 2024
Sun Oct 22 16:04:45 EDT 2023
Sun Mar 31 11:39:23 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords Autoimmunity
Human
Immunopathology
Ribonucleoprotein
Prognosis
Antibody
Autoantibody
Inflammation
Case study
Striated muscle disease
Etiology
Evolution
Female
Myositis
Diagnosis
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c481t-5c42c2ae450e73f8d22fd91128de58d4bf0ac6a78b0f43246ddc6e66ff74ddd23
Notes local:411040
ark:/67375/HXZ-64GKW8FL-L
PII:1460-2172
istex:5F52D150AA338DA8AEA6F29A8BCDD0BD3C56B248
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/rheumatology/article-pdf/41/9/1040/9533424/411040.pdf
PMID 12209039
PQID 195662620
PQPubID 41027
PageCount 7
ParticipantIDs proquest_miscellaneous_72057559
proquest_miscellaneous_21142719
proquest_journals_195662620
pubmed_primary_12209039
pascalfrancis_primary_13912541
istex_primary_ark_67375_HXZ_64GKW8FL_L
PublicationCentury 2000
PublicationDate 2002-09-01
PublicationDateYYYYMMDD 2002-09-01
PublicationDate_xml – month: 09
  year: 2002
  text: 2002-09-01
  day: 01
PublicationDecade 2000
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
– name: England
PublicationTitle Rheumatology (Oxford, England)
PublicationTitleAlternate Rheumatology
PublicationYear 2002
Publisher Oxford University Press
Oxford Publishing Limited (England)
Publisher_xml – name: Oxford University Press
– name: Oxford Publishing Limited (England)
SSID ssj0005138
Score 1.9102556
Snippet Objectives. Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue...
Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue diseases or...
Objectives. Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue...
OBJECTIVESInflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue...
SourceID proquest
pubmed
pascalfrancis
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 1040
SubjectTerms Adult
Anti‐ribonucleoprotein antibodies
Autoantibodies
Autoantibodies - immunology
Biological and medical sciences
Connective Tissue Diseases - complications
Connective Tissue Diseases - immunology
Connective Tissue Diseases - pathology
Dermatomyositis - complications
Dermatomyositis - immunology
Dermatomyositis - therapy
Diseases of striated muscles. Neuromuscular diseases
Electromyography
Female
Glucocorticoids - therapeutic use
Humans
Immunoglobulins, Intravenous - therapeutic use
Inflammatory myositis
Male
Medical sciences
Middle Aged
Muscle Weakness - etiology
Muscle Weakness - immunology
Muscle Weakness - therapy
Muscle, Skeletal - enzymology
Muscle, Skeletal - pathology
Muscle, Skeletal - physiopathology
Neurology
Retrospective Studies
Ribonucleoprotein, U1 Small Nuclear - immunology
RNA, Small Nuclear - immunology
Treatment Outcome
Title Inflammatory myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome
URI https://api.istex.fr/ark:/67375/HXZ-64GKW8FL-L/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/12209039
https://www.proquest.com/docview/195662620
https://search.proquest.com/docview/21142719
https://search.proquest.com/docview/72057559
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAviPvKYPgB8TKla5zESXiDstJt3SahVlS8RE5is2o0qZJmGvwN3vi1nJN7YeX2EkWuY7s-ny_H_s45hLwQugJdJ3ARvL5mKsPSHG4qjUvJ-4rbIHe0HT455aOpeTSzZp3O9xZrKVv5veDrtXYl_yNVSAO5opXsP0i2LhQS4B3kC0-QMDz_SsaHkQKBLoqL8sWXnH-V7omyxytiOfTdXJvqWrrAa-gIHRiLZC-Z-3H-HueuGuZRns-PkVVYWECnMKfInCiwueg9JS6hpbn9VZytgp98H7w_lxk2L_fzhI5NryoufRk8pHUQMYiXy3jN4mzwWWSXBYvgqEl9I6NPcabEGl357CKV0blEjxFJY19RnWawmq5VTcAmhzSjsKuuZmhTbyHRbU23oEv2W0s33ldfuywULrOS1n_GkE96z-01JbQ9cZ-eecPpeOxNDmaTG-Qms10L6aJvD48b-pCeR0mv21tZn7vGfrue_boW0H5w4F4h-1akMABVETlls2qTb3Emd8mdUjehrwug3SMdGd0nt05K9sUD8q2NN1qBgjagoAgKuoY3WuKN_oI32uDtFRW0QBuN1W8Kpg3aaIm2h2Q6PJgMRloZ1EMLTEdfaVZgsoAJaVp9aRvKCRlTIay4zAml5YSmr_oi4MJ2_L5Cb5E8DAMuOVfKNsMwZMYjshXFkdxGVp6hmIA1JAxhXy193zJc2E7DFhbUcMdkXfIy73FvWThu8URygTxG2_JGs48eN98df3CGY2_cJbtrIqk_APUIC9O7ZKeSkVeO_9RDS1uO8Ry65Hn9K0zOeOMmIhlnqcfQUt3W3c05bIYKkwU5Hheib-pmDM9Q3Sd__HaH3G6G0lOytUoy-Qy2yit_N8fsD3WpyEk
link.rule.ids 315,786,790,27955,27956
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inflammatory+myositis+associated+with+anti-U1-small+nuclear+ribonucleoprotein+antibodies%3A+a+subset+of+myositis+associated+with+a+favourable+outcome&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Coppo%2C+P&rft.au=Clauvel%2C+J+P&rft.au=Bengoufa%2C+D&rft.au=Oksenhendler%2C+E&rft.date=2002-09-01&rft.issn=1462-0324&rft.volume=41&rft.issue=9&rft.spage=1040&rft.epage=1046&rft_id=info:doi/10.1093%2Frheumatology%2F41.9.1040&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon